Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
MRK - Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
Merck Receives Positive EU CHMP Opinion For Keytruda® (Pembrolizumab) Plus Padcev® (Enfortumab Vedotin-Ejfv)
For best results when printing this announcement, please click on link below: Merck Receives Positive EU CHMP Opinion for KEYTRUDA(®) (pembrolizumab) Plus Padcev(®) (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) Opinion granted based on positive res